Cardinal Health (CAH)
(Delayed Data from NYSE)
$100.66 USD
-0.01 (-0.01%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $100.64 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$100.66 USD
-0.01 (-0.01%)
Updated Aug 12, 2024 04:00 PM ET
After-Market: $100.64 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth D Momentum A VGM
Zacks News
Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.
Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y
by Zacks Equity Research
Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.
Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.
Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails
by Zacks Equity Research
Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.
Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.
Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.
Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up
by Zacks Equity Research
Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.
Medtronic (MDT) Receives CE Mark Approval For Aurora System
by Zacks Equity Research
Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.
Reasons to Retain Patterson Companies (PDCO) Stock Now
by Zacks Equity Research
Investors are optimistic about Patterson Companies' (PDCO) strong product line.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Investors are optimistic about Neogen's (NEOG) strong performance across its Animal Safety and Food Safety segments.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors are optimistic about Abbott (ABT) owing to continued growth in the Diabetes business.
Edwards Lifesciences (EW) Gains on Innovation, Margin Growth
by Zacks Equity Research
In Edwards Lifesciences' (EW) Smart Recovery portfolio, the adoption of FloTrac and ClearSight sensors remains strong.
Integer Holdings (ITGR) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYD
3 Great Value Stocks to Buy Now for Steady Long-Term Growth
by Benjamin Rains
Exploring three highly-ranked value stocks with resilient businesses--(CAH), (GPK) and (BJ)--that investors might want to consider buying amid lingering inflation and for stable long-term expansion.
PacBio (PACB) Q4 Earnings Match Estimates, Revenues Top
by Zacks Equity Research
Despite robust Consumables revenues, PacBio (PACB) witnesses overall soft performance in the fourth quarter.
Nevro (NVRO) Q4 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q4, partly owing to robust domestic performance.
Zacks.com featured highlights include Microchip Technology, Caterpillar, Xcel Energy, Cardinal Health and Archer-Daniels-Midland
by Zacks Equity Research
Microchip Technology, Caterpillar, Xcel Energy, Cardinal Health and Archer-Daniels-Midland are part of the Zacks screen of the Week article.
Syneos Health (SYNH) Q4 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Higher reimbursable expenses and growth in Deployment Solutions contribute to Commercial Solutions revenue growth at Syneos Health (SYNH).
Bio-Rad (BIO) Q4 Earnings Miss Estimates, Operating Margin Up
by Zacks Equity Research
Excluding COVID-related sales, Life Science revenues at Bio-Rad (BIO) increase 28.1%, primarily driven by Droplet Digital PCR, process chromatography, Western blotting and qPCR products.
Cardinal Health, Inc. (CAH) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Cardinal (CAH). This makes it worthwhile to examine what the stock has in store.
AMN Healthcare (AMN) Q4 Earnings, Revenues Beat Estimates
by Zacks Equity Research
Despite AMN Healthcare's (AMN) robust results in the majority of its segments, it records a soft overall Q4 performance.
Amedisys (AMED) Q4 Earnings Beat, Operating Margin Dips
by Zacks Equity Research
Amedisys (AMED) delivers strong Home Health performance in the fourth quarter amid cost pressure.